‘Triple-G’ weight loss drug update: Even on the lowest dose, trial patients lost 12.7% of their weight — Live Feedhttps://www.live-feeds.com/feed/triple-g-weight-loss-drug-update-even-on-the-lowest-dose-trial-patients-lost-12-7-of-their-weightContinuously updated, source-cited coverage. Eli Lilly Triple-G Trial Shows 12.7% Weight Loss On Lowest Dosehttps://www.live-feeds.com/feed/triple-g-weight-loss-drug-update-even-on-the-lowest-dose-trial-patients-lost-12-7-of-their-weighthttps://www.live-feeds.com/feed/triple-g-weight-loss-drug-update-even-on-the-lowest-dose-trial-patients-lost-12-7-of-their-weight#u98913Sun, 04 Oct 2026 13:35:59 +0000Trial patients taking the lowest dose of Eli Lilly's experimental triple-hormone-receptor agonist retatrutide lost 12.7 percent of their body weight, according to recent updates from clinical studies. The drug targets three metabolic receptors including GLP-1, GIP, and glucagon, earning it the label of a next-generation obesity treatment. Across clinical evaluations, the drug has delivered substantial reductions, with average weight loss reaching about 50 pounds in certain contexts. Additionally, Eli Lilly reported data on combination regimens like EloraTZP, showing greater weight loss an